BIOCYTOGEN PHARMA. H YC1 (I54) — Free Cash Flow Generation Index

Latest as of December 2025: 0.76x

BIOCYTOGEN PHARMA. H YC1 (I54) has a Free Cash Flow Generation Index of 0.76x as of December 2025. Free cash flow of €282.43 Million represents 1% of operating cash flow (€370.25 Million). See BIOCYTOGEN PHARMA. H YC1 (I54) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

0.76x
Free Cash Flow / Operating CF

Free Cash Flow

€282.43 Million
EUR

Operating Cash Flow

€370.25 Million
EUR

Capital Expenditures

€87.82 Million
EUR

BIOCYTOGEN PHARMA. H YC1 Free Cash Flow Generation Index (2024–2025)

Historical FCF Generation Index trend for BIOCYTOGEN PHARMA. H YC1 across 2 annual periods. Explore I54 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for BIOCYTOGEN PHARMA. H YC1 (2024–2025)

Year-by-year Free Cash Flow Generation Index for BIOCYTOGEN PHARMA. H YC1. For the full company profile including market capitalisation, see BIOCYTOGEN PHARMA. H YC1 market capitalisation.

Year FCG Index Free Cash Flow (EUR) Operating CF Capital Expenditures YoY Change
2025 0.76x €282.43 Million €370.25 Million €87.82 Million ▼ -7.5%
2024 0.82x €174.12 Million €211.25 Million €37.13 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).